Brazilian clinical trials have unveiled that a COVID-19 vaccine developed by China's Sinovac has been found to be 50.4% effective, media reports said.
It shows the vaccine is significantly less effective than previous data suggested - barely over the 50% needed for regulatory approval, reports BBC.
The vaccine is one of the two which the Brazilian government has lined up.
Brazil is one of the worst-hit COVID-19 nations in the world.
Sinovac, a Beijing-based biopharmaceutical company, is behind CoronaVac, an inactivated vaccine. It works by using killed viral particles to expose the body's immune system to the virus without risking a serious disease response, reports BBC.
- Sudan: WHO supports battle against cholera in the east
- Ban smoking and vaping in schools worldwide urges WHO
- New global action pledge to end TB by 2030
- Healthcare: Lack of universal coverage, ‘human rights tragedy on a massive scale’
- WHO report claims proper hypertension treatment can avert 76 million deaths between 2023 and 2050